Tag Archives: advanced

#437745 Video Friday: Japan’s Giant Gundam ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here’s what we have so far (send us your events!):

AWS Cloud Robotics Summit – August 18-19, 2020 – [Online Conference]
CLAWAR 2020 – August 24-26, 2020 – [Virtual Conference]
ICUAS 2020 – September 1-4, 2020 – Athens, Greece
ICRES 2020 – September 28-29, 2020 – Taipei, Taiwan
AUVSI EXPONENTIAL 2020 – October 5-8, 2020 – [Online Conference]
IROS 2020 – October 25-29, 2020 – Las Vegas, Nev., USA
ICSR 2020 – November 14-16, 2020 – Golden, Co., USA
Let us know if you have suggestions for next week, and enjoy today’s videos.

It’s coming together—literally! Japan’s giant Gundam appears nearly finished and ready for its first steps. In a recent video, Gundam Factory Yokohama, which is constructing the 18-meter-tall, 25-ton walking robot, provided an update on the project. The video shows the Gundam getting its head attached—after being blessed by Shinto priests.

In the video update, they say the project is “steadily progressing” and further details will be announced around the end of September.

[ Gundam Factory Yokohama ]

Creating robots with emotional personalities will transform the usability of robots in the real-world. As previous emotive social robots are mostly based on statically stable robots whose mobility is limited, this work develops an animation to real-world pipeline that enables dynamic bipedal robots that can twist, wiggle, and walk to behave with emotions.

So that’s where Cassie’s eyes go.

[ Berkeley ]

Now that the DARPA SubT Cave Circuit is all virtual, here’s a good reminder of how it’ll work.

[ SubT ]

Since July 20, anyone 11+ years of age must wear a mask in closed public places in France. This measure also is highly recommended in many European, African and Persian Gulf countries. To support businesses and public places, SoftBank Robotics Europe unveils a new feature with Pepper: AI Face Mask Detection.

[ Softbank ]

University of Michigan researchers are developing new origami inspired methods for designing, fabricating and actuating micro-robots using heat.These improvements will expand the mechanical capabilities of the tiny bots, allowing them to fold into more complex shapes.

[ University of Michigan ]

Suzumori Endo Lab, Tokyo Tech has created various types of IPMC robots. Those robots are fabricated by novel 3D fabrication methods.

[ Suzimori Endo Lab ]

The most explode-y of drones manages not to explode this time.

[ SpaceX ]

At Amazon, we’re constantly innovating to support our employees, customers, and communities as effectively as possible. As our fulfillment and delivery teams have been hard at work supplying customers with items during the pandemic, Amazon’s robotics team has been working behind the scenes to re-engineer bots and processes to increase safety in our fulfillment centers.

While some folks are able to do their jobs at home with just a laptop and internet connection, it’s not that simple for other employees at Amazon, including those who spend their days building and testing robots. Some engineers have turned their homes into R&D labs to continue building these new technologies to better serve our customers and employees. Their creativity and resourcefulness to keep our important programs going is inspiring.

[ Amazon ]

Australian Army soldiers from 2nd/14th Light Horse Regiment (Queensland Mounted Infantry) demonstrated the PD-100 Black Hornet Nano unmanned aircraft vehicle during a training exercise at Shoalwater Bay Training Area, Queensland, on 4 May 2018.

This robot has been around for a long time—maybe 10 years or more? It makes you wonder what the next generation will look like, and if they can manage to make it even smaller.

[ FLIR ]

Event-based cameras are bio-inspired vision sensors whose pixels work independently from each other and respond asynchronously to brightness changes, with microsecond resolution. Their advantages make it possible to tackle challenging scenarios in robotics, such as high-speed and high dynamic range scenes. We present a solution to the problem of visual odometry from the data acquired by a stereo event-based camera rig.

[ Paper ] via [ HKUST ]

Emys can help keep kindergarteners sitting still for a long time, which is not small feat!

[ Emys ]

Introducing the RoboMaster EP Core, an advanced educational robot that was built to take learning to the next level and provides an all-in-one solution for STEAM-based classrooms everywhere, offering AI and programming projects for students of all ages and experience levels.

[ DJI ]

This Dutch food company Heemskerk uses ABB robots to automate their order picking. Their new solution reduces the amount of time the fresh produce spends in the supply chain, extending its shelf life, minimizing wastage, and creating a more sustainable solution for the fresh food industry.

[ ABB ]

This week’s episode of Pass the Torque features NASA’s Satellite Servicing Projects Division (NExIS) Robotics Engineer, Zakiya Tomlinson.

[ NASA ]

Massachusetts has been challenging Silicon Valley as the robotics capital of the United States. They’re not winning, yet. But they’re catching up.

[ MassTech ]

San Francisco-based Formant is letting anyone remotely take its Spot robot for a walk. Watch The Robot Report editors, based in Boston, take Spot for a walk around Golden Gate Park.

You can apply for this experience through Formant at the link below.

[ Formant ] via [ TRR ]

Thanks Steve!

An Institute for Advanced Study Seminar on “Theoretical Machine Learning,” featuring Peter Stone from UT Austin.

For autonomous robots to operate in the open, dynamically changing world, they will need to be able to learn a robust set of skills from relatively little experience. This talk begins by introducing Grounded Simulation Learning as a way to bridge the so-called reality gap between simulators and the real world in order to enable transfer learning from simulation to a real robot. It then introduces two new algorithms for imitation learning from observation that enable a robot to mimic demonstrated skills from state-only trajectories, without any knowledge of the actions selected by the demonstrator. Connections to theoretical advances in off-policy reinforcement learning will be highlighted throughout.

[ IAS ] Continue reading

Posted in Human Robots

#437721 Video Friday: Child Robot Learning to ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here’s what we have so far (send us your events!):

CLAWAR 2020 – August 24-26, 2020 – [Online Conference]
ICUAS 2020 – September 1-4, 2020 – Athens, Greece
ICRES 2020 – September 28-29, 2020 – Taipei, Taiwan
AUVSI EXPONENTIAL 2020 – October 5-8, 2020 – [Online Conference]
IROS 2020 – October 25-29, 2020 – Las Vegas, Nev., USA
CYBATHLON 2020 – November 13-14, 2020 – [Online Event]
ICSR 2020 – November 14-16, 2020 – Golden, Colo., USA
Let us know if you have suggestions for next week, and enjoy today’s videos.

We first met Ibuki, Hiroshi Ishiguro’s latest humanoid robot, a couple of years ago. A recent video shows how Ishiguro and his team are teaching the robot to express its emotional state through gait and body posture while moving.

This paper presents a subjective evaluation of the emotions of a wheeled mobile humanoid robot expressing emotions during movement by replicating human gait-induced upper body motion. For this purpose, we proposed the robot equipped with a vertical oscillation mechanism that generates such motion by focusing on human center-of-mass trajectory. In the experiment, participants watched videos of the robot’s different emotional gait-induced upper body motions, and assess the type of emotion shown, and their confidence level in their answer.

[ Hiroshi Ishiguro Lab ] via [ RobotStart ]

ICYMI: This is a zinc-air battery made partly of Kevlar that can be used to support weight, not just add to it.

Like biological fat reserves store energy in animals, a new rechargeable zinc battery integrates into the structure of a robot to provide much more energy, a team led by the University of Michigan has shown.

The new battery works by passing hydroxide ions between a zinc electrode and the air side through an electrolyte membrane. That membrane is partly a network of aramid nanofibers—the carbon-based fibers found in Kevlar vests—and a new water-based polymer gel. The gel helps shuttle the hydroxide ions between the electrodes. Made with cheap, abundant and largely nontoxic materials, the battery is more environmentally friendly than those currently in use. The gel and aramid nanofibers will not catch fire if the battery is damaged, unlike the flammable electrolyte in lithium ion batteries. The aramid nanofibers could be upcycled from retired body armor.

[ University of Michigan ]

In what they say is the first large-scale study of the interactions between sound and robotic action, researchers at CMU’s Robotics Institute found that sounds could help a robot differentiate between objects, such as a metal screwdriver and a metal wrench. Hearing also could help robots determine what type of action caused a sound and help them use sounds to predict the physical properties of new objects.

[ CMU ]

Captured on Aug. 11 during the second rehearsal of the OSIRIS-REx mission’s sample collection event, this series of images shows the SamCam imager’s field of view as the NASA spacecraft approaches asteroid Bennu’s surface. The rehearsal brought the spacecraft through the first three maneuvers of the sampling sequence to a point approximately 131 feet (40 meters) above the surface, after which the spacecraft performed a back-away burn.

These images were captured over a 13.5-minute period. The imaging sequence begins at approximately 420 feet (128 meters) above the surface – before the spacecraft executes the “Checkpoint” maneuver – and runs through to the “Matchpoint” maneuver, with the last image taken approximately 144 feet (44 meters) above the surface of Bennu.

[ NASA ]

The DARPA AlphaDogfight Trials Final Event took place yesterday; the livestream is like 5 hours long, but you can skip ahead to 4:39 ish to see the AI winner take on a human F-16 pilot in simulation.

Some things to keep in mind about the result: The AI had perfect situational knowledge while the human pilot had to use eyeballs, and in particular, the AI did very well at lining up its (virtual) gun with the human during fast passing maneuvers, which is the sort of thing that autonomous systems excel at but is not necessarily reflective of better strategy.

[ DARPA ]

Coming soon from Clearpath Robotics!

[ Clearpath ]

This video introduces Preferred Networks’ Hand type A, a tendon-driven robot gripper with passively switchable underactuated surface.

[ Preferred Networks ]

CYBATHLON 2020 will take place on 13 – 14 November 2020 – at the teams’ home bases. They will set up their infrastructure for the competition and film their races. Instead of starting directly next to each other, the pilots will start individually and under the supervision of CYBATHLON officials. From Zurich, the competitions will be broadcast through a new platform in a unique live programme.

[ Cybathlon ]

In this project, we consider the task of autonomous car racing in the top-selling car racing game Gran Turismo Sport. Gran Turismo Sport is known for its detailed physics simulation of various cars and tracks. Our approach makes use of maximum-entropy deep reinforcement learning and a new reward design to train a sensorimotor policy to complete a given race track as fast as possible. We evaluate our approach in three different time trial settings with different cars and tracks. Our results show that the obtained controllers not only beat the built-in non-player character of Gran Turismo Sport, but also outperform the fastest known times in a dataset of personal best lap times of over 50,000 human drivers.

[ UZH ]

With the help of the software pitasc from Fraunhofer IPA, an assembly task is no longer programmed point by point, but workpiece-related. Thus, pitasc adapts the assembly process itself for new product variants with the help of updated parameters.

[ Fraunhofer ]

In this video, a multi-material robot simulator is used to design a shape-changing robot, which is then transferred to physical hardware. The simulated and real robots can use shape change to switch between rolling gaits and inchworm gaits, to locomote in multiple environments.

[ Yale ]

This work presents a novel loco-manipulation control framework for the execution of complex tasks with kinodynamic constraints using mobile manipulators. As a representative example, we consider the handling and re-positioning of pallet jacks in unstructured environments. While these results reveal with a proof-of- concept the effectiveness of the proposed framework, they also demonstrate the high potential of mobile manipulators for relieving human workers from such repetitive and labor intensive tasks. We believe that this extended functionality can contribute to increasing the usability of mobile manipulators in different application scenarios.

[ Paper ] via [ IIT ]

I don’t know why this dinosaur ice cream serving robot needs to blow smoke out of its nose, but I like it.

[ Connected Robotics ] via [ RobotStart ]

Guardian S remote visual inspection and surveillance robots make laying cable runs in confined or hard to reach spaces easy. With advanced maneuverability and the ability to climb vertical, ferrous surfaces, the robot reaches areas that are not always easily accessible.

[ Sarcos ]

Looks like the company that bought Anki is working on an add-on to let cars charge while they drive.

[ Digital Dream Labs ]

Chris Atkeson gives a brief talk for the CMU Robotics Institute orientation.

[ CMU RI ]

A UofT Robotics Seminar, featuring Russ Tedrake from MIT and TRI on “Feedback Control for Manipulation.”

Control theory has an answer for just about everything, but seems to fall short when it comes to closing a feedback loop using a camera, dealing with the dynamics of contact, and reasoning about robustness over the distribution of tasks one might find in the kitchen. Recent examples from RL and imitation learning demonstrate great promise, but don’t leverage the rigorous tools from systems theory. I’d like to discuss why, and describe some recent results of closing feedback loops from pixels for “category-level” robot manipulation.

[ UofT ] Continue reading

Posted in Human Robots

#437716 Robotic Tank Is Designed to Crawl ...

Let’s talk about bowels! Most of us have them, most of us use them a lot, and like anything that gets used a lot, they eventually need to get checked out to help make sure that everything will keep working the way it should for as long as you need it to. Generally, this means a colonoscopy, and while there are other ways of investigating what’s going on in your gut, a camera on a flexible tube is still “the gold-standard method of diagnosis and intervention,” according to some robotics researchers who want to change that up a bit.

The University of Colorado’s Advanced Medical Technologies Lab has been working on a tank robot called Endoculus that’s able to actively drive itself through your intestines, rather than being shoved. The good news is that it’s very small, and the bad news is that it’s probably not as small as you’d like it to be.

The reason why a robot like Endoculus is necessary (or at least a good idea) is that trying to stuff a semi-rigid endoscopy tube into the semi-floppy tube that is your intestine doesn’t always go smoothly. Sometimes, the tip of the endoscopy tube can get stuck, and as more tube is fed in, it causes the intestine to distend, which best case is painful and worst case can cause serious internal injuries. One way of solving this is with swallowable camera pills, but those don’t help you with tasks like taking tissue samples. A self-propelled system like Endoculus could reduce risk while also making the procedure faster and cheaper.

Image: Advanced Medical Technologies Lab/University of Colorado

The researchers say that while the width of Endoculus is larger than a traditional endoscope, the device would require “minimal distention during use” and would “not cause pain or harm to the patient.” Future versions of the robot, they add, will “yield a smaller footprint.”

Endoculus gets around with four sets of treads, angled to provide better traction against the curved walls of your gut. The treads are micropillared, or covered with small nubs, which helps them deal with all your “slippery colon mucosa.” Designing the robot was particularly tricky because of the severe constraints on the overall size of the device, which is just 3 centimeters wide and 2.3 cm high. In order to cram the two motors required for full control, they had to be arranged parallel to the treads, resulting in a fairly complex system of 3D-printed worm gears. And to make the robot actually useful, it includes a camera, LED lights, tubes for injecting air and water, and a tool port that can accommodate endoscopy instruments like forceps and snares to retrieve tissue samples.

So far, Endoculus has spent some time inside of a live pig, although it wasn’t able to get that far since pig intestines are smaller than human intestines, and because apparently the pig intestine is spiraled somehow. The pig (and the robot) both came out fine. A (presumably different) pig then provided some intestine that was expanded to human-intestine size, inside of which Endoculus did much better, and was able to zip along at up to 40 millimeters per second without causing any damage. Personally, I’m not sure I’d want a robot to explore my intestine at a speed much higher than that.

The next step with Endoculus is to add some autonomy, which means figuring out how to do localization and mapping using the robot’s onboard camera and IMU. And then of course someone has to be the first human to experience Endoculus directly, which I’d totally volunteer for except the research team is in Colorado and I’m not. Sorry!

“Novel Optimization-Based Design and Surgical Evaluation of a Treaded Robotic Capsule Colonoscope,” by Gregory A. Formosa, J. Micah Prendergast, Steven A. Edmundowicz, and Mark E. Rentschler, from the University of Colorado, was presented at ICRA 2020.

< Back to IEEE Journal Watch Continue reading

Posted in Human Robots

#437707 Video Friday: This Robot Will Restock ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here's what we have so far (send us your events!):

CLAWAR 2020 – August 24-26, 2020 – [Online Conference]
ICUAS 2020 – September 1-4, 2020 – Athens, Greece
ICRES 2020 – September 28-29, 2020 – Taipei, Taiwan
AUVSI EXPONENTIAL 2020 – October 5-8, 2020 – [Online Conference]
IROS 2020 – October 25-29, 2020 – Las Vegas, Nev., USA
CYBATHLON 2020 – November 13-14, 2020 – [Online Event]
ICSR 2020 – November 14-16, 2020 – Golden, Colo., USA
Let us know if you have suggestions for next week, and enjoy today's videos.

Tokyo startup Telexistence has recently unveiled a new robot called the Model-T, an advanced teleoperated humanoid that can use tools and grasp a wide range of objects. Japanese convenience store chain FamilyMart plans to test the Model-T to restock shelves in up to 20 stores by 2022. In the trial, a human “pilot” will operate the robot remotely, handling items like beverage bottles, rice balls, sandwiches, and bento boxes.

With Model-T and AWP, FamilyMart and TX aim to realize a completely new store operation by remoteizing and automating the merchandise restocking work, which requires a large number of labor-hours. As a result, stores can operate with less number of workers and enable them to recruit employees regardless of the store’s physical location.

[ Telexistence ]

Quadruped dance-off should be a new robotics competition at IROS or ICRA.

I dunno though, that moonwalk might keep Spot in the lead…

[ Unitree ]

Through a hybrid of simulation and real-life training, this air muscle robot is learning to play table tennis.

Table tennis requires to execute fast and precise motions. To gain precision it is necessary to explore in this high-speed regimes, however, exploration can be safety-critical at the same time. The combination of RL and muscular soft robots allows to close this gap. While robots actuated by pneumatic artificial muscles generate high forces that are required for e.g. smashing, they also offer safe execution of explosive motions due to antagonistic actuation.

To enable practical training without real balls, we introduce Hybrid Sim and Real Training (HYSR) that replays prerecorded real balls in simulation while executing actions on the real system. In this manner, RL can learn the challenging motor control of the PAM-driven robot while executing ~15000 hitting motions.

[ Max Planck Institute ]

Thanks Dieter!

Anthony Cowley wrote in to share his recent thesis work on UPSLAM, a fast and lightweight SLAM technique that records data in panoramic depth images (just PNGs) that are easy to visualize and even easier to share between robots, even on low-bandwidth networks.

[ UPenn ]

Thanks Anthony!

GITAI’s G1 is the space dedicated general-purpose robot. G1 robot will enable automation of various tasks internally & externally on space stations and for lunar base development.

[ Gitai ]

The University of Michigan has a fancy new treadmill that’s built right into the floor, which proves to be a bit much for Mini Cheetah.

But Cassie Blue won’t get stuck on no treadmill! She goes for a 0.3 mile walk across campus, which ends when a certain someone ran the gantry into Cassie Blue’s foot.

[ Michigan Robotics ]

Some serious quadruped research going on at UT Austin Human Centered Robotics Lab.

[ HCRL ]

Will Burrard-Lucas has spent lockdown upgrading his slightly indestructible BeetleCam wildlife photographing robot.

[ Will Burrard-Lucas ]

Teleoperated surgical robots are becoming commonplace in operating rooms, but many are massive (sometimes taking up an entire room) and are difficult to manipulate, especially if a complication arises and the robot needs to removed from the patient. A new collaboration between the Wyss Institute, Harvard University, and Sony Corporation has created the mini-RCM, a surgical robot the size of a tennis ball that weighs as much as a penny, and performed significantly better than manually operated tools in delicate mock-surgical procedures. Importantly, its small size means it is more comparable to the human tissues and structures on which it operates, and it can easily be removed by hand if needed.

[ Harvard Wyss ]

Yaskawa appears to be working on a robot that can scan you with a temperature gun and then jam a mask on your face?

[ Motoman ]

Maybe we should just not have people working in mines anymore, how about that?

[ Exyn ]

Many current human-robot interactive systems tend to use accurate and fast – but also costly – actuators and tracking systems to establish working prototypes that are safe to use and deploy for user studies. This paper presents an embedded framework to build a desktop space for human-robot interaction, using an open-source robot arm, as well as two RGB cameras connected to a Raspberry Pi-based controller that allow a fast yet low-cost object tracking and manipulation in 3D. We show in our evaluations that this facilitates prototyping a number of systems in which user and robot arm can commonly interact with physical objects.

[ Paper ]

IBM Research is proud to host professor Yoshua Bengio — one of the world’s leading experts in AI — in a discussion of how AI can contribute to the fight against COVID-19.

[ IBM Research ]

Ira Pastor, ideaXme life sciences ambassador interviews Professor Dr. Hiroshi Ishiguro, the Director of the Intelligent Robotics Laboratory, of the Department of Systems Innovation, in the Graduate School of Engineering Science, at Osaka University, Japan.

[ ideaXme ]

A CVPR talk from Stanford’s Chelsea Finn on “Generalization in Visuomotor Learning.”

[ Stanford ] Continue reading

Posted in Human Robots

#437673 Can AI and Automation Deliver a COVID-19 ...

Illustration: Marysia Machulska

Within moments of meeting each other at a conference last year, Nathan Collins and Yann Gaston-Mathé began devising a plan to work together. Gaston-Mathé runs a startup that applies automated software to the design of new drug candidates. Collins leads a team that uses an automated chemistry platform to synthesize new drug candidates.

“There was an obvious synergy between their technology and ours,” recalls Gaston-Mathé, CEO and cofounder of Paris-based Iktos.

In late 2019, the pair launched a project to create a brand-new antiviral drug that would block a specific protein exploited by influenza viruses. Then the COVID-19 pandemic erupted across the world stage, and Gaston-Mathé and Collins learned that the viral culprit, SARS-CoV-2, relied on a protein that was 97 percent similar to their influenza protein. The partners pivoted.

Their companies are just two of hundreds of biotech firms eager to overhaul the drug-discovery process, often with the aid of artificial intelligence (AI) tools. The first set of antiviral drugs to treat COVID-19 will likely come from sifting through existing drugs. Remdesivir, for example, was originally developed to treat Ebola, and it has been shown to speed the recovery of hospitalized COVID-19 patients. But a drug made for one condition often has side effects and limited potency when applied to another. If researchers can produce an ­antiviral that specifically targets SARS-CoV-2, the drug would likely be safer and more effective than a repurposed drug.

There’s one big problem: Traditional drug discovery is far too slow to react to a pandemic. Designing a drug from scratch typically takes three to five years—and that’s before human clinical trials. “Our goal, with the combination of AI and automation, is to reduce that down to six months or less,” says Collins, who is chief strategy officer at SRI Biosciences, a division of the Silicon Valley research nonprofit SRI International. “We want to get this to be very, very fast.”

That sentiment is shared by small biotech firms and big pharmaceutical companies alike, many of which are now ramping up automated technologies backed by supercomputing power to predict, design, and test new antivirals—for this pandemic as well as the next—with unprecedented speed and scope.

“The entire industry is embracing these tools,” says Kara Carter, president of the International Society for Antiviral Research and executive vice president of infectious disease at Evotec, a drug-discovery company in Hamburg. “Not only do we need [new antivirals] to treat the SARS-CoV-2 infection in the population, which is probably here to stay, but we’ll also need them to treat future agents that arrive.”

There are currentlyabout 200 known viruses that infect humans. Although viruses represent less than 14 percent of all known human pathogens, they make up two-thirds of all new human pathogens discovered since 1980.

Antiviral drugs are fundamentally different from vaccines, which teach a person’s immune system to mount a defense against a viral invader, and antibody treatments, which enhance the body’s immune response. By contrast, anti­virals are chemical compounds that directly block a virus after a person has become infected. They do this by binding to specific proteins and preventing them from functioning, so that the virus cannot copy itself or enter or exit a cell.

The SARS-CoV-2 virus has an estimated 25 to 29 proteins, but not all of them are suitable drug targets. Researchers are investigating, among other targets, the virus’s exterior spike protein, which binds to a receptor on a human cell; two scissorlike enzymes, called proteases, that cut up long strings of viral proteins into functional pieces inside the cell; and a polymerase complex that makes the cell churn out copies of the virus’s genetic material, in the form of single-stranded RNA.

But it’s not enough for a drug candidate to simply attach to a target protein. Chemists also consider how tightly the compound binds to its target, whether it binds to other things as well, how quickly it metabolizes in the body, and so on. A drug candidate may have 10 to 20 such objectives. “Very often those objectives can appear to be anticorrelated or contradictory with each other,” says Gaston-Mathé.

Compared with antibiotics, antiviral drug discovery has proceeded at a snail’s pace. Scientists advanced from isolating the first antibacterial molecules in 1910 to developing an arsenal of powerful antibiotics by 1944. By contrast, it took until 1951 for researchers to be able to routinely grow large amounts of virus particles in cells in a dish, a breakthrough that earned the inventors a Nobel Prize in Medicine in 1954.

And the lag between the discovery of a virus and the creation of a treatment can be heartbreaking. According to the World Health Organization, 71 million people worldwide have chronic hepatitis C, a major cause of liver cancer. The virus that causes the infection was discovered in 1989, but effective antiviral drugs didn’t hit the market until 2014.

While many antibiotics work on a range of microbes, most antivirals are highly specific to a single virus—what those in the business call “one bug, one drug.” It takes a detailed understanding of a virus to develop an antiviral against it, says Che Colpitts, a virologist at Queen’s University, in Canada, who works on antivirals against RNA viruses. “When a new virus emerges, like SARS-CoV-2, we’re at a big disadvantage.”

Making drugs to stop viruses is hard for three main reasons. First, viruses are the Spartans of the pathogen world: They’re frugal, brutal, and expert at evading the human immune system. About 20 to 250 nanometers in diameter, viruses rely on just a few parts to operate, hijacking host cells to reproduce and often destroying those cells upon departure. They employ tricks to camouflage their presence from the host’s immune system, including preventing infected cells from sending out molecular distress beacons. “Viruses are really small, so they only have a few components, so there’s not that many drug targets available to start with,” says Colpitts.

Second, viruses replicate quickly, typically doubling in number in hours or days. This constant copying of their genetic material enables viruses to evolve quickly, producing mutations able to sidestep drug effects. The virus that causes AIDS soon develops resistance when exposed to a single drug. That’s why a cocktail of antiviral drugs is used to treat HIV infection.

Finally, unlike bacteria, which can exist independently outside human cells, viruses invade human cells to propagate, so any drug designed to eliminate a virus needs to spare the host cell. A drug that fails to distinguish between a virus and a cell can cause serious side effects. “Discriminating between the two is really quite difficult,” says Evotec’s Carter, who has worked in antiviral drug discovery for over three decades.

And then there’s the money barrier. Developing antivirals is rarely profitable. Health-policy researchers at the London School of Economics recently estimated that the average cost of developing a new drug is US $1 billion, and up to $2.8 billion for cancer and other specialty drugs. Because antivirals are usually taken for only short periods of time or during short outbreaks of disease, companies rarely recoup what they spent developing the drug, much less turn a profit, says Carter.

To change the status quo, drug discovery needs fresh approaches that leverage new technologies, rather than incremental improvements, says Christian Tidona, managing director of BioMed X, an independent research institute in Heidelberg, Germany. “We need breakthroughs.”

Putting Drug Development on Autopilot
Earlier this year, SRI Biosciences and Iktos began collaborating on a way to use artificial intelligence and automated chemistry to rapidly identify new drugs to target the COVID-19 virus. Within four months, they had designed and synthesized a first round of antiviral candidates. Here’s how they’re doing it.

1/5

STEP 1: Iktos’s AI platform uses deep-learning algorithms in an iterative process to come up with new molecular structures likely to bind to and disable a specific coronavirus protein. Illustrations: Chris Philpot

2/5

STEP 2: SRI Biosciences’s SynFini system is a three-part automated chemistry suite for producing new compounds. Starting with a target compound from Iktos, SynRoute uses machine learning to analyze and optimize routes for creating that compound, with results in about 10 seconds. It prioritizes routes based on cost, likelihood of success, and ease of implementation.

3/5

STEP 3: SynJet, an automated inkjet printer platform, tests the routes by printing out tiny quantities of chemical ingredients to see how they react. If the right compound is produced, the platform tests it.

4/5

STEP 4: AutoSyn, an automated tabletop chemical plant, synthesizes milligrams to grams of the desired compound for further testing. Computer-selected “maps” dictate paths through the plant’s modular components.

5/5

STEP 5: The most promising compounds are tested against live virus samples.

Previous
Next

Iktos’s AI platform was created by a medicinal chemist and an AI expert. To tackle SARS-CoV-2, the company used generative models—deep-learning algorithms that generate new data—to “imagine” molecular structures with a good chance of disabling a key coronavirus protein.

For a new drug target, the software proposes and evaluates roughly 1 million compounds, says Gaston-Mathé. It’s an iterative process: At each step, the system generates 100 virtual compounds, which are tested in silico with predictive models to see how closely they meet the objectives. The test results are then used to design the next batch of compounds. “It’s like we have a very, very fast chemist who is designing compounds, testing compounds, getting back the data, then designing another batch of compounds,” he says.

The computer isn’t as smart as a human chemist, Gaston-Mathé notes, but it’s much faster, so it can explore far more of what people in the field call “chemical space”—the set of all possible organic compounds. Unexplored chemical space is huge: Biochemists estimate that there are at least 1063 possible druglike molecules, and that 99.9 percent of all possible small molecules or compounds have never been synthesized.

Still, designing a chemical compound isn’t the hardest part of creating a new drug. After a drug candidate is designed, it must be synthesized, and the highly manual process for synthesizing a new chemical hasn’t changed much in 200 years. It can take days to plan a synthesis process and then months to years to optimize it for manufacture.

That’s why Gaston-Mathé was eager to send Iktos’s AI-generated designs to Collins’s team at SRI Biosciences. With $13.8 million from the Defense Advanced Research Projects Agency, SRI Biosciences spent the last four years automating the synthesis process. The company’s automated suite of three technologies, called SynFini, can produce new chemical compounds in just hours or days, says Collins.

First, machine-learning software devises possible routes for making a desired molecule. Next, an inkjet printer platform tests the routes by printing out and mixing tiny quantities of chemical ingredients to see how they react with one another; if the right compound is produced, the platform runs tests on it. Finally, a tabletop chemical plant synthesizes milligrams to grams of the desired compound.

Less than four months after Iktos and SRI Biosciences announced their collaboration, they had designed and synthesized a first round of antiviral candidates for SARS-CoV-2. Now they’re testing how well the compounds work on actual samples of the virus.

Out of 10
63 possible druglike molecules, 99.9 percent have never been synthesized.

Theirs isn’t the only collaborationapplying new tools to drug discovery. In late March, Alex Zhavoronkov, CEO of Hong Kong–based Insilico Medicine, came across a YouTube video showing three virtual-reality avatars positioning colorful, sticklike fragments in the side of a bulbous blue protein. The three researchers were using VR to explore how compounds might bind to a SARS-CoV-2 enzyme. Zhavoronkov contacted the startup that created the simulation—Nanome, in San Diego—and invited it to examine Insilico’s ­AI-generated molecules in virtual reality.

Insilico runs an AI platform that uses biological data to train deep-learning algorithms, then uses those algorithms to identify molecules with druglike features that will likely bind to a protein target. A four-day training sprint in late January yielded 100 molecules that appear to bind to an important SARS-CoV-2 protease. The company recently began synthesizing some of those molecules for laboratory testing.

Nanome’s VR software, meanwhile, allows researchers to import a molecular structure, then view and manipulate it on the scale of individual atoms. Like human chess players who use computer programs to explore potential moves, chemists can use VR to predict how to make molecules more druglike, says Nanome CEO Steve McCloskey. “The tighter the interface between the human and the computer, the more information goes both ways,” he says.

Zhavoronkov sent data about several of Insilico’s compounds to Nanome, which re-created them in VR. Nanome’s chemist demonstrated chemical tweaks to potentially improve each compound. “It was a very good experience,” says Zhavoronkov.

Meanwhile, in March, Takeda Pharmaceutical Co., of Japan, invited Schrödinger, a New York–based company that develops chemical-simulation software, to join an alliance working on antivirals. Schrödinger’s AI focuses on the physics of how proteins interact with small molecules and one another.

The software sifts through billions of molecules per week to predict a compound’s properties, and it optimizes for multiple desired properties simultaneously, says Karen Akinsanya, chief biomedical scientist and head of discovery R&D at Schrödinger. “There’s a huge sense of urgency here to come up with a potent molecule, but also to come up with molecules that are going to be well tolerated” by the body, she says. Drug developers are seeking compounds that can be broadly used and easily administered, such as an oral drug rather than an intravenous drug, she adds.

Schrödinger evaluated four protein targets and performed virtual screens for two of them, a computing-intensive process. In June, Google Cloud donated the equivalent of 16 million hours of Nvidia GPU time for the company’s calculations. Next, the alliance’s drug companies will synthesize and test the most promising compounds identified by the virtual screens.

Other companies, including Amazon Web Services, IBM, and Intel, as well as several U.S. national labs are also donating time and resources to the Covid-19 High Performance Computing Consortium. The consortium is supporting 87 projects, which now have access to 6.8 million CPU cores, 50,000 GPUs, and 600 petaflops of computational resources.

While advanced technologies could transform early drug discovery, any new drug candidate still has a long road after that. It must be tested in animals, manufactured in large batches for clinical trials, then tested in a series of trials that, for antivirals, lasts an average of seven years.

In May, the BioMed X Institute in Germany launched a five-year project to build a Rapid Antiviral Response Platform, which would speed drug discovery all the way through manufacturing for clinical trials. The €40 million ($47 million) project, backed by drug companies, will identify ­outside-the-box proposals from young scientists, then provide space and funding to develop their ideas.

“We’ll focus on technologies that allow us to go from identification of a new virus to 10,000 doses of a novel potential therapeutic ready for trials in less than six months,” says BioMed X’s Tidona, who leads the project.

While a vaccine will likely arrive long before a bespoke antiviral does, experts expect COVID-19 to be with us for a long time, so the effort to develop a direct-acting, potent antiviral continues. Plus, having new antivirals—and tools to rapidly create more—can only help us prepare for the next pandemic, whether it comes next month or in another 102 years.

“We’ve got to start thinking differently about how to be more responsive to these kinds of threats,” says Collins. “It’s pushing us out of our comfort zones.”

This article appears in the October 2020 print issue as “Automating Antivirals.” Continue reading

Posted in Human Robots